Latest news

• Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more

  AstraZeneca for rights to its former blockbuster Seroquel and Seroquel XR in international markets. ... The company will acquire rights to Seroquel and Seroquel XR in 51 countries and regions including China, the UK, Brazil, Australia, Saudi Arabia,

• AZ expects return to growth this year after 2017 decline

  to $2.6bn, although the cumulative effect of patent expiries - which also affect antipsychotic Seroquel XR (quetiapine) and gastrointestinal drug Nexium (esomeprazole) - are starting to dissipate.

• AZ CEO says company’s renaissance is on track

  for cholesterol drug Crestor (rosuvastatin) and antipsychotic Seroquel XR (quetiapine).

• US appeals court upholds AstraZeneca’s Seroquel XR patent

  These include Teva, which launched its own versions of both Seroquel XR and Seroquel in the UK in March 2012. ... But it isn't just Seroquel XR that AZ is trying to prolong the life of.

• AZ's Q3 income up as sales stay flat

  The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort